Precision Health Reports Announces Improved Lipoprotein Management Goals in their Cardiometabolic Risk Assessment
Newly harmonized guidelines implemented into the personalized assessments further the shared decision-making and risk reduction strategies to reduce individual disease risk.
LITTLE ROCK, AR – August 8, 2023 – Precision Health Reports, a pioneer in cutting-edge health cardiometabolic risk assessment solutions, is thrilled to announce the release of a significant enhancement to its renowned Cardiometabolic Risk Assessment product. This latest update reflects the emerging harmonization between prominent guidelines and recommendations from key medical associations, including the American College of Cardiology (ACC), the European Society of Cardiology (ESC), and the Diabetes Care and Research in Metabolism (DCRM).
The key part of this product enhancement lies in the presentation of "threshold goals," for atherogenic lipid/lipoprotein values to reflect this harmonized guideline approach for individual management of heart attack and stroke risk. Designed to reflect the minimally acceptable reduction in these biomarkers that are necessary for risk reduction in specific risk groups, these threshold goals reflect a clearer approach toward personalized health optimization.
"Precision Health Reports is dedicated to empowering individuals to take control of their health journey through informed decision-making," said Dr. William Cromwell, Chief Medical Officer at Precision Health Reports. " Our updated Cardiometabolic Risk Assessment leverages the latest insights from expert guidelines to give healthcare providers and patients comprehensive insight into individual cardiometabolic risk and specific individual goals. This improves the shared decision-making conversation between patients and their physicians to develop strategies to reduce cardiometabolic risk."
The core of the Assessment update revolves around determining the proper reduction for atherogenic lipids/lipoproteins that are tailored to an individual's risk group. This strategy is rooted in the understanding that sustained reductions in ApoB levels contribute significantly to risk mitigation. As a result, individuals are encouraged to maintain values well below the threshold goal for their respective risk group.
"At Precision Health Reports, we believe that early, personalized risk identification and intervention is a valuable tool in extending healthspan," said Matt Martin, CEO of Precision Health Reports. "Our enhanced Cardiometabolic Risk Assessment product is a testament to our commitment to a guideline-centric design, as we empower shared decision-making."
This groundbreaking update to the Cardiometabolic Risk Assessment product reinforces Precision Health Reports' commitment to powering clinical shared decision-making, driving meaningful change in personalized health management and risk reduction strategies.
Learn more about our harmonized lipoprotein management goals at: https://precisionhealthreports.com/harmonized-lipoprotein-management-goals.
About Precision Health Reports
Precision Health Reports is a digital health services company focused on powering shared decision-making for individual cardiometabolic disease risk. Co-founded by Matt Martin and renowned lipidologist William Cromwell, MD in April 2020, Precision Health Reports delivers a comprehensive personalized assessment report to primary care providers that uniquely integrates the complex guidelines for comprehensive and precision risk identification for each of their patients. To learn more about Precision Health Reports, visit https://precisionhealthreports.com or find us on Facebook, Instagram, Twitter, or LinkedIn.
###
Precision Health Reports contact:
Matthew Martin, 919.601.5005 or hello@precisionhealthreports.com